Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano Sells 326 Shares

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Roxanne Lagano also recently made the following trade(s):

• On Tuesday, February 11th, Roxanne Lagano sold 326 shares of Zoetis stock. The shares were sold at an average price of $171.18, for a total value of $55,804.68.

Zoetis Trading Down 1.6 %

Zoetis stock opened at $161.74 on Thursday. The stock has a market cap of $72.43 billion, a PE ratio of 29.57, a P/E/G ratio of 2.78 and a beta of 0.94. The stock has a 50-day moving average price of $166.92 and a 200 day moving average price of $176.44. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Institutional Trading of Zoetis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Atlantic Edge Private Wealth Management LLC increased its position in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its stake in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after buying an additional 166 shares during the last quarter. Navigoe LLC acquired a new stake in Zoetis in the 4th quarter worth about $30,000. Darwin Wealth Management LLC acquired a new stake in Zoetis in the 3rd quarter worth about $31,000. Finally, Capital Performance Advisors LLP acquired a new stake in Zoetis in the 3rd quarter worth about $33,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.